NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

Active Not RecruitingEARLY_Phase 1

Sponsor: ECOG-ACRIN Cancer Research Group

Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm

Interventions: Quality-of-Life Assessment, Questionnaire Administration

Countries: United States

This clinical trial gathers information about adolescents and young adults (AYA) and patient reported outcomes data in Eastern Cooperative Oncology Group (ECOG)-American College of Radiology Imaging Network (ACRIN) trials to improve the collection of AYA patient reported outcomes. This study may help doctors understand the needs of adolescent and young adult cancer patients.

Eligibility overview

Sex: ALL

Age: 18 Years to 39 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Patient must be \>= 18 years and =\< 39 years of age at registration
* Patient must have a histologically confirmed diagnosis of primary cancer of any stage within 12 weeks (84 days) at registration
* Patient must not have a recurrence or second primary cancer
* Patients must not have basal cell skin carcinoma
* Patient must have received, be currently receiving or planning to receive treatment for cancer, including surgery and/or chemotherapy and/or radiation therapy
* Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-3
* Patient must have a life expectancy \> 24 months
* Patient must be able to complete questionnaires in English or in Spanish
* Patient must have internet access through computer, tablet, or smartphone
* Patient must have an email address
* Patient must have a mobile phone able with text messaging capabilities
* Patient must be able to accurately provide self-report data (e.g. per clinical judgment, cognitive function is intact)
* Patient must be able to provide informed consent
* Participation in clinical trials is not an exclusionary criterion in EAQ202. Patients may be dually enrolled in EAQ202 as well as in therapeutic trials, including those involving checkpoint inhibitors

  * NOTE: We understand that some therapeutic trials may also collect PRO data (e.g., the cross-National Clinical Trials Network \[NCTN\] S1826 study in which ECOG-ACRIN is participating), thus creating a potential for overburdening patients. We will be attentive to informing all patients of this potential overburdening as they consider a voluntary decision to register for EAQ202. We will coordinate with the PRO chair(s) of the therapeutic studies to ensure that the integrity of the PRO analyses be preserved

Locations (347)

Fairbanks, Alaska, United States
Kingman, Arizona, United States
Phoenix, Arizona, United States
Fort Smith, Arkansas, United States
Hot Springs, Arkansas, United States
Little Rock, Arkansas, United States
Arroyo Grande, California, United States
Arroyo Grande, California, United States
Carmichael, California, United States
Carmichael, California, United States
Dublin, California, United States
Elk Grove, California, United States
Emeryville, California, United States
Emeryville, California, United States
Martinez, California, United States
Merced, California, United States
Oakland, California, United States
Rocklin, California, United States
Sacramento, California, United States
San Luis Obispo, California, United States
Santa Maria, California, United States
Walnut Creek, California, United States
Walnut Creek, California, United States
Woodland, California, United States
Aurora, Colorado, United States
Aurora, Colorado, United States
Boulder, Colorado, United States
Boulder, Colorado, United States
Centennial, Colorado, United States
Colorado Springs, Colorado, United States
+ 317 more on CT.gov